Cervarix Gets One Up On Gardasil In Cross-Protection: HPV-31 In FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
More limited cross protection claim approved by FDA still gives GSK a selling point in its effort to dislodge Merck's Gardasil from its exclusive position in the U.S. HPV protection vaccine market.
You may also be interested in...
Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA
Industry is calling on FDA to write separate rules for assessing adjuvants. This would encourage innovation in immunotherapies, the Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America contend.
Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA
Industry is calling on FDA to write separate rules for assessing adjuvants. This would encourage innovation in immunotherapies, the Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America contend.
Gardasil Anal Cancer Indication To Face FDA Advisory Committee Scrutiny
Supplemental application filed earlier this year is part of Merck's strategy to broaden use of the HPV vaccine, although its bid to expand the label to women ages 27-45 has thus far been blocked by the agency.